Novartis to Squeeze Out MorphoSys Minority Shareholders, Initiate Delisting
Novartis to Squeeze Out MorphoSys Minority Shareholders, Initiate Delisting
诺华将强制收购morphosys的少数股东，并开始退市
MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders.
2024年5月，MorphoSys AG(股票代码: MOR)与Novartis BidCo AG和诺华制药达成退市协议，经成功完成收购。Novartis BidCo Germany AG(下称“Novartis”，与Novartis BidCo AG和诺华制药一起)还通知了MorphoSys他们将通过挤出少数股东的方式将MorphoSys合并至Novartis。
In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash...
2024年4月，诺华制药以68欧元的现金价(收购要...
登录免费看全文
登录/注册